Table 3 Response in patients with AML-MRC treated with azacitidine or CCR
All patients with AML-MRC (N = 262) | ||||
|---|---|---|---|---|
AZA (n = 129) | CCR (n = 133) | |||
n (%) | ||||
Overall Response Rate (CR + CRi) | 32 (24.8) | 23 (17.3) | ||
CR | 25 (19.4) | 20 (15.0) | ||
CRi | 7 (5.4) | 3 (2.3) | ||
Partial remission | 1 (0.8) | 2 (1.5) | ||
Stable disease | 46 (35.7) | 38 (28.6) | ||
Progressive disease | 11 (8.5) | 16 (12.0) | ||
AML-MRC patients with Intermediate-risk cytogenetics | AML-MRC patients with Poor-risk cytogenetics | |||
AZA (n = 63) | CCR (n = 61) | AZA (n = 66) | CCR (n = 72) | |
n (%) | ||||
Overall Response Rate (CR + CRi) | 21 (33.3) | 15 (24.6) | 11 (16.7) | 8 (11.1) |
CR | 18 (28.6) | 13 (21.3) | 7 (10.6) | 7 (9.7) |
CRi | 3 (4.8) | 2 (3.3) | 4 (6.1) | 1 (1.4) |
Partial remission | 1 (1.6) | 1 (1.6) | 0 | 1 (1.4) |
Stable disease | 25 (39.7) | 18 (29.5) | 21 (31.8) | 20 (27.8) |
Progressive disease | 6 (9.5) | 5 (8.2) | 5 (7.6) | 11 (15.3) |
AML-MRC patients ages 65–74 years | AML-MRC patients ages ≥ 75 years | |||
AZA (n = 52) | CCR (n = 64) | AZA (n = 77) | CCR (n = 69) | |
n (%) | ||||
Overall Response Rate (CR + CRi) | 15 (28.8) | 16 (25.0) | 17 (22.1) | 7 (10.1) |
CR | 11 (21.2) | 14 (21.9) | 14 (18.2) | 6 (8.7) |
CRi | 4 (7.7) | 2 (3.1) | 3 (3.9) | 1 (1.4) |
Partial remission | 0 | 2 (3.1) | 1 (1.3) | 0 |
Stable disease | 20 (38.5) | 24 (37.5) | 26 (33.8) | 14 (20.3) |
Progressive disease | 5 (9.6) | 6 (9.4) | 6 (7.8) | 10 (14.5) |